Thursday, September 14, 2023 1:45:40 PM
Patent Extensions for NWBO are ongoing.
Per your comments,
"There are very limited ways for patents to get extended. They do not include just filing new patents with extra features."
In the case of NWBO, the majority of their patents are in the medical based sector where as the USPTO and other patent granting facilities all over the world grant patent extensions for medical based sectors.
The USPTO
https://www.uspto.gov/patents/laws/patent-terms-extended
https://www.uspto.gov/patents/laws/patent-term-extension/patent-terms-extended-under-35-usc-156#:~:text=Applications%20for%20patent%20term%20extension%20under%2035%20U.S.C.,awaiting%20premarket%20government%20approval%20from%20a%20regulatory%20agency.
The bottom line, good news for NWBO and their patents with respect to the patent office, and the patent office understands that extensions are necessary, and one of the main reasons is in light of the ongoing obstacles facing NWBO and other companies in this patent sector, IMPO.
Per your comments,
"There are very limited ways for patents to get extended. They do not include just filing new patents with extra features."
In the case of NWBO, the majority of their patents are in the medical based sector where as the USPTO and other patent granting facilities all over the world grant patent extensions for medical based sectors.
The USPTO
https://www.uspto.gov/patents/laws/patent-terms-extended
https://www.uspto.gov/patents/laws/patent-term-extension/patent-terms-extended-under-35-usc-156#:~:text=Applications%20for%20patent%20term%20extension%20under%2035%20U.S.C.,awaiting%20premarket%20government%20approval%20from%20a%20regulatory%20agency.
The bottom line, good news for NWBO and their patents with respect to the patent office, and the patent office understands that extensions are necessary, and one of the main reasons is in light of the ongoing obstacles facing NWBO and other companies in this patent sector, IMPO.
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
